Apnimed Raises $62.5M to Advance Lead Sleep Apnea Pill Candidate to Phase 3
Additional data from Apnimed’s Phase 2 MARIPOSA study later this year will inform the final design of the planned Phase 3 studies.
Additional data from Apnimed’s Phase 2 MARIPOSA study later this year will inform the final design of the planned Phase 3 studies.
Medical device companies are developing smart sensors for oral appliances that will measure parameters of sleep such as AHI and even brain wave activity.
Advances in materials and technology mean oral appliance users have every opportunity to get their original bites back.
One key factor driving Inspire's growth achieved during Q1 was the performance of the company's Advisor Care Program.
In this study, the research team assessed whether these associations are explained by causal effects of sleep traits on blood sugar levels.
Sleep study autoscoring is starting to go beyond simply calculating the apnea-hypopnea index.
The acquisition of APIRx will significantly strengthen Incannex's position with regard to cannabinoid and psychedelic treatment development.
Ancient humans may have evolved to slumber efficiently — and in a crowd.
According to the company, the new directors bring a diverse set of experiences, along with a passion for growth and innovation in the medical device and healthcare sectors.